Onconova Therapeutics Inc. (Nasdaq: ONTX) submitted an investigational new
drug application to the Food and Drug Administration for a Phase 3 trial
of IV rigosertib in higher-risk myelodysplastic syndromes. The stock price climbed 64 cents to $2.62.
Onconova Therapeutics submits NDA
August 14, 2015 at 13:14 PM EDT
